4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. - Wikidata - wikimedia - TriplyDB

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

http://www.wikidata.org/entity/Q35778060

about

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression mTOR signaling in growth control and disease Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Amino acid management in cancer Targeting cancer with kinase inhibitors mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions Signaling cross-talk in the resistance to HER family receptor targeted therapy Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue Maximising the potential of AKT inhibitors as anti-cancer treatments mTOR signaling in tumorigenesis S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution PI3K and cancer: lessons, challenges and opportunities p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.Where now for anti-EGF receptor therapies in colorectal cancer?The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins.Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.New frontiers in translational control of the cancer genome ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.The identification of perillyl alcohol glycosides with improved antiproliferative activity Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail.Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.Merkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus.The evolution of the TOR pathway and its role in cancer.Genetically engineered mouse models of PI3K signaling in breast cancer.Alternative dosing of dual PI3K and MEK inhibition in cancer therapy.

P2860

Q24306326-E99F1677-E6D9-4D15-858E-ACE5F1EF7E0C Q24609227-2681A26A-920E-4C1A-9C96-1F8A97425303 Q24632821-3EEA1E2D-C171-428D-9B10-D89C31398A09 Q24634174-34ECBC21-544A-4B33-AEDD-5B4D86F798B7 Q26739777-CECE106C-F7B9-4813-89C1-C9815917E94A Q26751344-D94F15C8-A7F6-40E1-99E7-A2359A3A5EAE Q26795609-271487C1-9E6B-4CE1-B99E-8256463282D7 Q26798087-4943126C-B089-4BA8-B32A-71B98C509E4D Q26865765-5070C140-7829-4BD4-BEE1-7847F5680833 Q27007511-A825442D-057B-4059-8EB8-360B19B1B80B Q27027778-8409B7CB-E2C0-4220-AF11-18338B05A7D9 Q27334924-F26A275A-EAEA-4B6F-9698-D2396B9BE371 Q27350187-D91BBA59-B74D-4428-A5A4-4F327388BB57 Q27851674-78687C09-E3FA-4901-A33E-FA3E85C5B9AB Q27851698-2DF52518-1CEC-40AA-8234-B30EEED14F04 Q27852093-3A5A1547-EA03-4A72-B0BD-7577BD77B257 Q27852894-DCEE0D1A-5242-4648-8820-10C2E8563326 Q28066868-79BAAC69-D1D8-48AD-A555-31695B55E8BA Q28072254-48ADFD7F-A20F-4040-B483-102636AA7464 Q28252695-8E1FF839-5B77-4FB5-B8DD-C2FD763DD788 Q28477972-D32A6284-264C-4EC8-9DEB-A457760848EF Q28547017-FD6027CE-5046-41A9-8751-3119DABB9254 Q28655705-A4BAF69F-E8FC-410A-B1D0-58A8E3E80F49 Q30080017-4A4D8AE6-BBB4-4679-8384-4DD2EC976AF9 Q30371561-80E810C5-2968-47DC-AF87-9FC4A0572016 Q31038305-BAFCBBB6-EE90-4789-A824-D501B7D1EC15 Q33591361-A766EF59-9BA8-4DD1-ACDB-A0FA7E57D0C4 Q33726847-2F7A83B4-C1FF-4C1C-82DA-39948A5D7445 Q33751074-F7CD0670-F2F4-40EF-B6F5-0AC03DD22A4A Q33767369-47727660-8EFF-429A-B23F-B8E0BAE16B52 Q33853235-4DE8BED9-56B3-4D76-8825-3E965853C9E8 Q34104165-DC6949D3-4776-47E3-B443-DF64A400A8BE Q34105105-5F909E2A-62A2-4196-84DD-6A882B5A8DA0 Q34164891-78229352-8729-4EEB-8AD3-463444416E67 Q34227565-0F6ECD0D-8A12-4FBC-94FA-A7E2873E68C1 Q34291001-BDF06DD5-AE6A-4830-ACE0-D600C75784A4 Q34309882-3657E482-3115-4C0E-8526-2897655C440B Q34318188-0F54E8B1-ABA1-4ECD-8F22-4B929F427D60 Q34332175-9FF572BD-A37C-4466-8459-C195F968C2B7 Q34520111-6EE89BE2-086B-4E03-B1D8-D391940E92D0

P2860

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.

http://www.wikidata.org/entity/Q35778060

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

4E-BP1 is a key effector of th ...... ates their function in tumors.

@ast

4E-BP1 is a key effector of th ...... ates their function in tumors.

@en

type

label

4E-BP1 is a key effector of th ...... ates their function in tumors.

@ast

4E-BP1 is a key effector of th ...... ates their function in tumors.

@en

prefLabel

4E-BP1 is a key effector of th ...... ates their function in tumors.

@ast

4E-BP1 is a key effector of th ...... ates their function in tumors.

@en

P1433

Q35778060-2FEA5E91-414D-41C7-A824-3307BF1DE2B2

P1476

Q35778060-FFA90AB1-2A0E-4081-81F7-94DD099F89FE

P2093

Q35778060-013C1A56-0C36-4C09-B315-637912564288

Q35778060-05FB7CAA-0B50-4903-B63B-C8C477CC01AA

Q35778060-0CF3CC43-9BFE-4281-A980-6B32D47A8A2F

Q35778060-14FB5CD5-F74F-408E-ABE8-E12983F5B67E

Q35778060-76CFA167-71D8-48D5-99E8-0E34226CE086

Q35778060-CB2A770E-8BF7-4450-A567-89502EC3F59F

Q35778060-CBEE85C9-F4E2-4FD3-9D4A-60BDAFC39A35

Q35778060-CD2C73EA-AE68-4257-A2DD-D6F49D3A5F02

P2860

Q35778060-04E88023-3E59-4E5B-86BA-4D6112C8FAD2

Q35778060-06BEDA1C-112B-4F95-BBB2-A6D259D8ADE5

Q35778060-0A2786CD-C10A-4166-8880-424F34B9F648

Q35778060-0F4C3FA1-8327-4C18-926B-66D6693FF563

Q35778060-12814BDB-AFB8-457C-9D2F-B320457E7024

Q35778060-143E5588-3107-4C84-A5E8-6D84B9DFA65A

Q35778060-1C562321-B44B-4BC2-9AB0-16F1A30FDD1B

Q35778060-21B2F1B1-3C9E-493D-BEAB-705A5FDDEE43

Q35778060-2780E896-44D3-4E81-883A-88C5BB6AABF7

Q35778060-320BE204-B72E-46FF-B3F3-27AF8E07C5A7

P304

Q35778060-B4F3AED0-CE86-4BAE-85B7-37F92306E426

P31

Q35778060-73144802-9864-477F-A2A8-564C43ED9143

P356

Q35778060-33742EB7-7903-4B8E-A75E-E816B2C2F4CD

P433

Q35778060-C229CD65-EEAD-47C4-B4BB-AF34AD6FFC74

P478

Q35778060-F162385C-4283-403E-BDFB-FDF5FBC2E063

P577

Q35778060-F3D3599D-A897-43A9-B0F9-7FAC2C544564

P5875

Q35778060-19F728DB-1E01-4E9E-BAFE-9118AC7E3599

P698

Q35778060-3019D28C-BFC4-433C-B2ED-6093115CC5B7

P932

Q35778060-A9A5EF0D-68A7-47E1-B92B-1FEC38BC688D

P356

J.CCR.2010.05.023

P1433

P1476

4E-BP1 is a key effector of th ...... ates their function in tumors.

@en

P2093

David B Solit

http://www.w3.org/2001/XMLSchema#string

Ensar Halilovic

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Qing Ye

http://www.w3.org/2001/XMLSchema#string

Qing-Bai She

http://www.w3.org/2001/XMLSchema#string

Senji Shirasawa

http://www.w3.org/2001/XMLSchema#string

Takehiko Sasazuki

http://www.w3.org/2001/XMLSchema#string

Wei Zhen

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Tumours with PI3K activation are resistant to dietary restriction

AKT/PKB signaling: navigating downstream

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

High frequency of mutations of the PIK3CA gene in human cancers

P304

39-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2010.05.023

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45100273

http://www.w3.org/2001/XMLSchema#string

P698

20609351

http://www.w3.org/2001/XMLSchema#string

P932

3286650

http://www.w3.org/2001/XMLSchema#string